Mainz Biomed (NASDAQ:MYNZ) Trading Down 5.3% – What’s Next?

Mainz Biomed (NASDAQ:MYNZ)’s stock price dropped 5.3% on Wednesday . The company traded as low as $4.24 and last traded at $4.32. Approximately 53,969 shares were traded during mid-day trading, an increase of 22% from the average daily volume of 44,295 shares. The stock had previously closed at $4.56.

Analyst Ratings Changes

Separately, HC Wainwright cut shares of Mainz Biomed from a “buy” rating to a “neutral” rating in a report on Monday, November 25th.

Mainz Biomed Price Performance

The business has a fifty day simple moving average of $7.52 and a two-hundred day simple moving average of $11.76. The company has a market cap of $8.60 million, a PE ratio of -0.07 and a beta of 0.06.

About Mainz Biomed

Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer.